Medicare Overpaid $15 Million for Roche Cancer Drug, OIG Says
This article is for subscribers only.
Medicare, the U.S. health insurance program for the elderly and disabled, overpaid for Roche Holding AG’s Herceptin breast-cancer treatment by about $15 million, according to a government investigation.
Health-care providers across the country charged Medicare for amounts of the drug they didn’t administer to patients, running afoul of billing guidelines, according to a series of reports issued by the U.S. Department of Health and Human Services’ Office of the Inspector General. The OIG examined billing records from 2008 through 2010.